{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:34:26Z","timestamp":1746084866907,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10637-021-01184-5","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T11:55:49Z","timestamp":1632484549000},"page":"124-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7283-0519","authenticated-orcid":false,"given":"Rony","family":"Dev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda L.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrazzak","family":"Zarifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya A.","family":"Albittar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi Rodon","family":"Ahnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"1184_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M (2015) Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? Oncologist 20:576\u2013583","journal-title":"Oncologist"},{"key":"1184_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, Ettinger DS, Aston J et al (2017) NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw 15:883\u2013893","journal-title":"J Natl Compr Canc Netw"},{"key":"1184_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00520-003-0478-0","volume":"11","author":"Drug Utilization Review Team (DURTO)","year":"2003","unstructured":"Drug Utilization Review Team (DURTO) (2003) Antiemetic prescriptions in Italian breast cancer patients submitted to adjuvant chemotherapy. Support Care Cancer 11:785\u2013789","journal-title":"Support Care Cancer"},{"key":"1184_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD (2011) Definition and classification of cancer cachexia; an international consensus. Lancet Oncol 12:489\u2013495","journal-title":"Lancet Oncol"},{"key":"1184_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1477-2574.2010.00178.x","volume":"12","author":"KC Fearon","year":"2010","unstructured":"Fearon KC, Baracos VE (2010) Cachexia in pancreatic cancer: new treatment option and measure of success. HPB (Oxford) 12:323\u2013324","journal-title":"HPB (Oxford)"},{"key":"1184_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134\u2013142","journal-title":"N Engl J Med"},{"key":"1184_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokyama O et al (2020) Olanzapine 5mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (j-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249","journal-title":"Lancet Oncol"},{"key":"1184_CR8","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1007\/s00520-020-05380-6","volume":"28","author":"S Ithimakin","year":"2020","unstructured":"Ithimakin S, Theeratrakul P, Laocharoenkiat A et al (2020) Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer 28:5335\u20135342","journal-title":"Support Care Cancer"},{"key":"1184_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4143\/crt.2017.577","volume":"51","author":"SY Jeon","year":"2019","unstructured":"Jeon SY, Han HS, Baie WK et al (2019) A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. Cancer Res Treat 51:90\u201397","journal-title":"Cancer Res Treat"},{"key":"1184_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00520-016-3386-9","volume":"25","author":"S Mukhopadhyay","year":"2017","unstructured":"Mukhopadhyay S, Kwatra KPA, Badyal D (2017) Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer 25:145\u2013154","journal-title":"Support Care Cancer"},{"key":"1184_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.21037\/apm.2019.08.04","volume":"8","author":"P Tienchaiananda","year":"2019","unstructured":"Tienchaiananda P, Nipondhkit W, Maneenil K et al (2019) A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Ann Palliat Med 8:372\u2013380","journal-title":"Ann Palliat Med"},{"key":"1184_CR12","first-page":"895","volume":"6","author":"RM Navari","year":"2020","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG et al (2020) Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and\/or Vomiting: A Randomized Pilot Trial JAMA. Oncol 6:895\u2013899","journal-title":"Oncol"},{"key":"1184_CR13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00520-009-0739-7","volume":"18","author":"RM Navari","year":"2010","unstructured":"Navari RM, Brenner MC (2010) Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 18:951\u2013956","journal-title":"Support Care Cancer"},{"key":"1184_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","volume":"27","author":"HY Fung","year":"2014","unstructured":"Fung HY, Chook YM (2014) Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol 27:52\u201361","journal-title":"Semin Cancer Biol"},{"key":"1184_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcancer.2014.04.005","volume":"27","author":"WT Senapedis","year":"2014","unstructured":"Senapedis WT, Baloglu E, Landesman Y (2014) Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol 27:74\u201386","journal-title":"Semin Cancer Biol"},{"key":"1184_CR16","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F et al (2020) Selinexor in patients with relapsed or refractory diffuse large b-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 7:e511-522","journal-title":"Lancet Haematol"},{"key":"1184_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M et al (2019) Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med 381:727\u2013738","journal-title":"N Engl J Med"},{"key":"1184_CR18","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.annonc.2020.08.679","volume":"31","author":"KZ Thein","year":"2020","unstructured":"Thein KZ, Tsimberidou AM, Piha-Paul SA et al (2020) Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase 1b study. Ann Oncol 31:S486. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.679","journal-title":"Ann Oncol"},{"key":"1184_CR19","doi-asserted-by":"publisher","first-page":"S756","DOI":"10.1016\/j.annonc.2020.08.1247","volume":"31","author":"IC Glitza","year":"2020","unstructured":"Glitza IC, Patel S, Zarifa A et al (2020) Phase 1b study to evaluate the safety of selinexor in combination with pembrolizumab in patients with advanced malignancies-the melanoma experience. Ann Oncol 31:S756. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1247","journal-title":"Ann Oncol"},{"key":"1184_CR20","doi-asserted-by":"publisher","first-page":"S480","DOI":"10.1016\/j.annonc.2020.08.668","volume":"31","author":"KZ Thein","year":"2020","unstructured":"Thein KZ, Tsimberidou AM, Piha-Paul SA et al (2020) Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study. Ann Oncol 31:S480. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.668","journal-title":"Ann Oncol"},{"key":"1184_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","volume":"46","author":"MC Mauri","year":"2007","unstructured":"Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007) Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relations hip between plasma concentration and clinical response. Clin Pharmacokinet 46:359\u2013388","journal-title":"Clin Pharmacokinet"},{"key":"1184_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00004714-199906000-00014","volume":"19","author":"S Gupta","year":"1999","unstructured":"Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B (1999) Olanzapine: weight gain and therapeutic efficacy. J Clin Psychoparmacol 19:273\u2013275","journal-title":"J Clin Psychoparmacol"},{"key":"1184_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4088\/JCP.v62n0204","volume":"62","author":"BJ Kinon","year":"2001","unstructured":"Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62:92\u2013100","journal-title":"J Clin Psychiatry"},{"key":"1184_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","volume":"722","author":"RM Navari","year":"2014","unstructured":"Navari RM (2014) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 722:180\u2013186","journal-title":"Eur J Pharmacol"},{"key":"1184_CR25","doi-asserted-by":"crossref","unstructured":"Hocking CM, Kichenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 22:1143\u20131151","DOI":"10.1007\/s00520-014-2138-y"},{"key":"1184_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/(SICI)1099-1611(200001\/02)9:1<84::AID-PON440>3.0.CO;2-T","volume":"9","author":"WF Pirl","year":"2000","unstructured":"Pirl WF, Roth AJ (2000) Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 9:84\u201387","journal-title":"Psychooncology"},{"key":"1184_CR27","doi-asserted-by":"crossref","unstructured":"Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B (2018) Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev 9:CD012555","DOI":"10.1002\/14651858.CD012555.pub2"},{"key":"1184_CR28","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"R Navari","year":"2013","unstructured":"Navari R, Nagy C, Gray S (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care Cancer 21:1655\u20131663","journal-title":"Supportive Care Cancer"},{"key":"1184_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00520-016-3445-2","volume":"25","author":"M Nakagaki","year":"2017","unstructured":"Nakagaki M, Barras M, Curley C, Butler J, Kennedy G (2017) A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 25:607\u2013613","journal-title":"Support Care Cancer"},{"key":"1184_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/ecc.12260","volume":"24","author":"J Liu","year":"2015","unstructured":"Liu J, Tan L, Zhang H et al (2015) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care 24:436\u2013443","journal-title":"Eur J Cancer Care"},{"key":"1184_CR31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clml.2017.06.012","volume":"17","author":"S Trifilio","year":"2017","unstructured":"Trifilio S, Welles C, Seeger K et al (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: A retrospective study. Clin lymphoma Meyeloma Luek 17:584\u2013589","journal-title":"Clin lymphoma Meyeloma Luek"},{"key":"1184_CR32","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1634\/theoncologist.2018-0140","volume":"24","author":"T Yokoe","year":"2019","unstructured":"Yokoe T, Hayashida T, Nagayama A et al (2019) Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist 24:e347-357","journal-title":"Oncologist"},{"key":"1184_CR33","first-page":"294","volume":"16","author":"CC O\u2019Sullivan","year":"2018","unstructured":"O\u2019Sullivan CC, Van Houten HK, Snagaralingham LR et al (2018) Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Higly Emetogenic Chemotherapy. JNCCN 16:294\u2013299","journal-title":"JNCCN"},{"key":"1184_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/cap.2007.135","volume":"18","author":"JT McCracken","year":"2008","unstructured":"McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J (2008) Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 18:501\u2013508","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1184_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/1044546041648959","volume":"14","author":"RJ Stephens","year":"2004","unstructured":"Stephens RJ, Bassel C, Sandor P (2004) Olanzapine in the treatment of aggression and ticks in children with Tourette\u2019s syndrome-a pilot study. J Child Adolesc Psychopharmacol 14:255\u2013266","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1184_CR36","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00520-015-2625-9","volume":"23","author":"A Naing","year":"2015","unstructured":"Naing A, Dalal S, Abdelrahim M et al (2015) Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer 23:2649\u20132654","journal-title":"Support Care Cancer"},{"key":"1184_CR37","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.2147\/CMAR.S191330","volume":"11","author":"H Okamoto","year":"2019","unstructured":"Okamoto H, Shono K, Nozaki-Taguchi N (2019) Low-dose of olanzapine has ameliorating effects on cancer-related anorexia. Cancer Manag Res 11:2233\u20132239","journal-title":"Cancer Manag Res"},{"key":"1184_CR38","unstructured":"Moleman P (2009) Antipsychotica. In Praktische Psychofarmacologie 189\u2013273. Houten, The Netherlands: Prelum Uitgevers"},{"key":"1184_CR39","unstructured":"Anonymous (2017) Zyprexa 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg coated tablets. Zyprexa Velotab 5 mg, 10 mg, 15 mg, and 20 mg orodispersible tablets. www.medicines.org.uk\/emc\/medicine\/614 Accessed 10 Nov 2020"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01184-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01184-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01184-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:40:09Z","timestamp":1678509609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01184-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01184-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB approval obtained by institution, University of Texas MD Anderson Cancer Center and Informed consent was obtained by all participants of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained by all participants of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Dr. Hui reports funding from Helsinn for investigator initiated studies outside of submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"COI"}},{"value":"IRB approval obtained by institution, University of Texas MD Anderson Cancer Center and Informed consent was obtained by all participants of the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"none.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}